|Alt. symbols||SIGLEC3, SIGLEC-3, gp67|
|Locus||Chr. 19 q13.3|
The extracellular portion of this receptor contains two immunoglobulin domains (one IgV and one IgC2 domain), placing CD33 within the immunoglobulin superfamily. The intracellular portion of CD33 contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that are implicated in inhibition of cellular activity.
CD33 was the target of gemtuzumab ozogamicin, a monoclonal antibody-based treatment for acute myeloid leukemia, (treatment voluntarily withdrawn from the market in 2010). However, Anti-CD33 monoclonal antibodies are extensively used for the diagnosis of all types of AMLs.
- Garnache-Ottou F, Chaperot L, Biichle S et al. (February 2005). "Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells". Blood 105 (3): 1256–64. doi:10.1182/blood-2004-06-2416. PMID 15388576.
- Hernández-Caselles T, Martínez-Esparza M, Pérez-Oliva AB et al. (January 2006). "A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing". J. Leukoc. Biol. 79 (1): 46–58. doi:10.1189/jlb.0205096. PMID 16380601.
- Myeloid cell surface antigen CD33 precursor - Homo sapiens (Human)
- Walter RB, Gooley TA, van der Velden VH et al. (May 2007). "CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy". Blood 109 (10): 4168–70. doi:10.1182/blood-2006-09-047399. PMC 1885511. PMID 17227830.
|This article on a gene on chromosome 19 is a stub. You can help Wikipedia by expanding it.|